{"id":100195,"date":"2023-05-17T05:14:01","date_gmt":"2023-05-17T05:14:01","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=109972"},"modified":"2023-05-17T05:14:01","modified_gmt":"2023-05-17T05:14:01","slug":"nyxoah-reports-first-quarter-2023-financial-and-operating-results","status":"publish","type":"post","link":"https:\/\/lebanonnewsgazette.com\/nyxoah-reports-first-quarter-2023-financial-and-operating-results\/","title":{"rendered":"Nyxoah Reports First Quarter 2023 Financial and Operating Results"},"content":{"rendered":"
REGULATED INFORMATION<\/strong><\/p>\n Nyxoah Reports First Quarter 2023 Financial and Operating Results<\/strong><\/p>\n Mont-Saint-Guibert, Belgium \u2013 May 16, 2023 10:05pm CET \/ 4:05pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/strong>\u00a0(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2023.<\/p>\n Recent Financial and Operating Highlights<\/strong><\/p>\n \u201cIn 2023, our focus is in the U.S. on DREAM patient follow up resulting in reaching the primary endpoints. I am excited by the data on the first 34 patients and look forward to sharing the full abstract results at SLEEP 2023 next month. Our increasing conviction in DREAM outcomes is accelerating investment in our commercial organization, starting with the addition of Christoph as Chief Commercial Officer,\u201d commented Olivier Taelman, Nyxoah\u2019s Chief Executive Officer. \u201cChristoph\u2019s hire, along with the\u00a0\u20ac19 million raised from key investors, puts us in a strong position as we embark on our next stage of growth.\u201d<\/p>\n First Quarter 2023 Results<\/strong><\/p>\n UNAUDITED CONDENSED CONSOLIDATED FINANCIAL INFORMATION \u2013 CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS\u00a0FOR THE THREE MONTHS ENDED MARCH 31, 2023<\/strong>\u00a0\u00a0(in thousands)<\/strong><\/p>\n \u00a0UNAUDITED CONDENSED CONSOLIDATED FINANCIAL INFORMATION \u2013 CONSOLIDATED STATEMENT\u00a0OF FINANCIAL POSITION\u00a0AS OF MARCH 31, 2023 (in thousands)<\/strong><\/p>\n\n
\n\n
\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n For the three months ended March 31<\/strong><\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n <\/td>\n 2023<\/strong><\/td>\n \u00a0<\/strong><\/td>\n 2022<\/strong><\/td>\n<\/tr>\n \n Revenue<\/td>\n <\/td>\n <\/td>\n \u20ac441<\/td>\n <\/td>\n \u20ac660<\/td>\n<\/tr>\n \n Cost of goods sold<\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n (175)<\/td>\n <\/td>\n (289)<\/td>\n<\/tr>\n \n Gross profit<\/strong><\/td>\n <\/td>\n <\/td>\n \u20ac266<\/strong><\/td>\n <\/td>\n \u20ac371<\/strong><\/td>\n<\/tr>\n \n Research and Development Expense<\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n (6,157)<\/td>\n <\/td>\n (3,595)<\/td>\n<\/tr>\n \n Selling, General and Administrative Expense<\/td>\n <\/td>\n <\/td>\n (5,551)<\/td>\n <\/td>\n (4,193)<\/td>\n<\/tr>\n \n Other income\/(expense)<\/td>\n <\/td>\n <\/td>\n 46<\/td>\n <\/td>\n 136<\/td>\n<\/tr>\n \n Operating loss for the period<\/strong><\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n \u20ac(11,396)<\/strong><\/td>\n <\/td>\n \u20ac(7,281)<\/strong><\/td>\n<\/tr>\n \n Financial income<\/td>\n <\/td>\n <\/td>\n 625<\/td>\n <\/td>\n 1,576<\/td>\n<\/tr>\n \n Financial expense<\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n (958)<\/td>\n <\/td>\n (788)<\/td>\n<\/tr>\n \n Loss for the period before taxes<\/strong><\/td>\n <\/td>\n <\/td>\n \u20ac(11,729)<\/strong><\/td>\n <\/td>\n \u20ac(6,493)<\/strong><\/td>\n<\/tr>\n \n Income taxes<\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n (182)<\/td>\n <\/td>\n (208)<\/td>\n<\/tr>\n \n Loss for the period<\/strong><\/td>\n <\/td>\n <\/td>\n \u20ac(11,911)<\/strong><\/td>\n <\/td>\n \u20ac(6,701)<\/strong><\/td>\n<\/tr>\n \n \u00a0<\/strong><\/td>\n <\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n<\/tr>\n \n Loss attributable to equity holders<\/strong><\/td>\n <\/td>\n <\/td>\n \u20ac(11,911)<\/strong><\/td>\n <\/td>\n \u20ac(6,701)<\/strong><\/td>\n<\/tr>\n \n Other comprehensive loss<\/strong><\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n Items that may be subsequently reclassified to profit or
\nloss (net of tax)<\/strong><\/td>\n<\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n Currency translation differences<\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n (28)<\/td>\n <\/td>\n ( 102)<\/td>\n<\/tr>\n \n Total comprehensive loss for the year, net of tax<\/strong><\/td>\n <\/td>\n <\/td>\n \u20ac(11,939)<\/strong><\/td>\n <\/td>\n \u20ac(6,803)<\/strong><\/td>\n<\/tr>\n \n Loss attributable to equity holders<\/strong><\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n \u20ac(11,939)<\/strong><\/td>\n <\/td>\n \u20ac(6,803)<\/strong><\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n Basic Loss Per Share (in EUR)<\/td>\n <\/td>\n <\/td>\n \u20ac(0.460)<\/td>\n <\/td>\n \u20ac(0.260)<\/td>\n<\/tr>\n \n Diluted Loss Per Share (in EUR)<\/td>\n <\/td>\n <\/td>\n \u20ac(0.460)<\/td>\n <\/td>\n \u20ac(0.260)<\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n \n\n
\n <\/td>\n<\/tr>\n \n <\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n As at<\/strong><\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n <\/td>\n <\/td>\n March 31
\n2023<\/strong><\/td>\n\u00a0<\/strong><\/td>\n December 31 2022<\/strong><\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n ASSETS<\/strong><\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Non-current assets<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Property, plant and equipment<\/td>\n <\/td>\n <\/td>\n \u20ac2,721<\/td>\n <\/td>\n \u20ac2,460<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Intangible assets<\/td>\n <\/td>\n <\/td>\n 42,447<\/td>\n \u00a0<\/strong><\/td>\n 39,972<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Right of use assets<\/td>\n <\/td>\n <\/td>\n 3,669<\/td>\n <\/td>\n 3,159<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Deferred tax asset<\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n 50<\/td>\n \u00a0<\/strong><\/td>\n 47<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Other long-term receivables<\/td>\n <\/td>\n <\/td>\n 169<\/td>\n <\/td>\n 173<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u20ac49,056<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u20ac45,811<\/strong><\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Current assets<\/strong><\/td>\n <\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Inventory<\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n 1,249<\/td>\n \u00a0<\/strong><\/td>\n 882<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Trade receivables<\/td>\n <\/td>\n <\/td>\n 1,499<\/td>\n <\/td>\n 1,463<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Other receivables<\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n 1,419<\/td>\n \u00a0<\/strong><\/td>\n 1,775<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Other current assets<\/td>\n <\/td>\n <\/td>\n 1,663<\/td>\n <\/td>\n 1,284<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Financial assets<\/td>\n <\/td>\n <\/td>\n 62,403<\/td>\n <\/td>\n 76,968<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Cash and cash equivalents<\/td>\n <\/td>\n <\/td>\n 33,664<\/td>\n <\/td>\n 17,888<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n <\/td>\n \u20ac101,897<\/strong><\/td>\n <\/td>\n \u20ac100,260<\/strong><\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Total assets<\/strong><\/td>\n <\/td>\n <\/td>\n \u20ac150,953<\/strong><\/td>\n <\/td>\n \u20ac146,071<\/strong><\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n EQUITY AND LIABILITIES<\/strong><\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Capital and reserves<\/strong><\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Capital<\/td>\n <\/td>\n <\/td>\n 4,859<\/td>\n <\/td>\n 4,440<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Share premium<\/td>\n <\/td>\n <\/td>\n 243,488<\/td>\n \u00a0<\/strong><\/td>\n 228,275<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Share based payment reserve<\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n 6,582<\/td>\n <\/td>\n 5,645<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Other comprehensive income<\/td>\n <\/td>\n <\/td>\n 148<\/td>\n \u00a0<\/strong><\/td>\n 176<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Retained loss<\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n (130,051)<\/td>\n <\/td>\n (118,212)<\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n Total equity attributable to shareholders<\/strong><\/td>\n <\/td>\n <\/td>\n \u20ac125,026<\/strong><\/td>\n <\/td>\n \u20ac120,324<\/strong><\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n LIABILITIES<\/strong><\/td>\n